In patients with oligometastatic prostate cancer, metastasis-directed therapy plus standard of care was associated with significant improvements in progression-free survival (PFS), radiographic PFS, ...

For patients with impairment on the G8, the median OS was 6.8 months (95% CI, 2.4-10.1), compared with 14 months (95% CI, 9.9-not evaluable; P =.0110) for patients without impairment on the G8. Use of ...

For prostate cancer patients with low-volume tumors and metastasis, the median overall survival was 37.13 months. Prostate cancer patients with metastatic disease and low-volume primary tumors appear ...

(RTTNews) - IDEAYA Biosciences, Inc. (IDYA) has announced the completion of targeted full enrolment of 435 patients in its OptimuUM-02 Phase 2/3 trial, evaluating Darovasertib in combination with ...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced detailed results from the Phase 3 HER2CLIMB-05 trial of the tyrosine kinase inhibitor TUKYSA ® (tucatinib) as part of an ...

TUKYSA, trastuzumab, and pertuzumab reduced the risk of disease progression or death by 36% compared to trastuzumab and pertuzumab alone in Phase 3 HER2CLIMB-05 study The combination demonstrated a ...

A key Zcash developer has published the first detailed blueprint for a dynamic fee market, opening a community discussion about how the decade-old network should price transactions as ZEC’s price, ...

No significant toxicities observed in 11 patients included in study; 10 were alive at median follow-up of 2.6 years. HealthDay News — For young patients with primary multimetastatic Ewing sarcoma, ...

Responses were rapid and durable, and tumor shrinkage was observed in 82 percent of patients New findings from this investigational study build on the strength of RYBREVANT® (amivantamab-vmjw) in ...

Positive results from the TROPION-Breast02 Phase III trial showed DATROWAY® (datopotamab deruxtecan-dlnk) demonstrated a statistically significant and clinically meaningful improvement for the dual ...